Moreover, quantitative RT-PCR analysis revealed that mRNA levels of prostate specific antigen (PSA), an AR target that is often used as a measure of androgen receptor signaling and marker of prostate cancer progression [55], significantly decreased following NSC treatment, especially in combination with nutlin-3 (Figure 4C). This evidence concerns the gene AR and prostate carcinoma.